Literaturverzeichnis zum Artikel „Neues aus der Kardiologie“
von Professor Dr. Melchior Seyfarth und Professor Dr. Albert Schömig, Heft 10/2008, Seite 592-596
1. Thygesen K, Alpert JS, White HD, et al. Universal Definition of Myocardial Infarction.
Circulation 2007;116:2634-2653.
2. Authors/Task Force M, Bassand J-P, Hamm CW, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007;28:1598-1660.
3. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous throm- bolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. The Lancet 2003;361:13-20.
4. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarc- tion: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians:
2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guide- lines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008;117:296-329.
5. Hamm CW. Leitlinien der DGK: Akutes Koronarsyndrom (ACS) Teil 2: Akutes Koro- narsyndrom mit ST-Hebung. Z Kardiol 2004;93:324-41.
6. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. The Lancet;367:569-578.
7. Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in Patients with ST- Elevation Myocardial Infarction. N Engl J Med 2008;358:2205-2217.
8. Investigators) MJeafB-. Abciximab in Patients with AMI Undergoing Primary PCI After Clopidogrel Pretreatment. J Am Coll Cardiol 2008;ACC Meeting 2008 (Late Breaking Clinical Trial).
9. Mehta SR, Cannon CP, Fox KAA, et al. Routine vs Selective Invasive Strategies in Patients With Acute Coronary Syndromes: A Collaborative Meta-analysis of Random- ized Trials. JAMA 2005;293:2908-2917.
10. Neumann F-J, Kastrati A, Schwarzer G. New aspects in the treatment of acute coro- nary syndromes without ST-elevation: ICTUS and ISAR-COOL in perspective. Eur Heart J 2007;9:A4-A10.
11. Hausleiter J, Meyer T, Hadamitzky M, et al. Non-invasive coronary computed tomo- graphic angiography for patients with suspected coronary artery disease: the Coro- nary Angiography by Computed Tomography with the Use of a Submillimeter resolu- tion (CACTUS) trial. Eur Heart J 2007;28:3034-3041.
12. Hausleiter J, Meyer T, Hadamitzky M, et al. Radiation Dose Estimates From Cardiac Multislice Computed Tomography in Daily Practice: Impact of Different Scanning Pro- tocols on Effective Dose Estimates. Circulation 2006;113:1305-1310.
13. Boden WE, O'Rourke RA, Teo KK, et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N Engl J Med 2007;356:1503-1516.
14. Schömig A, Mehilli J, Waha Ad, Seyfarth M, Pache J, Kastrati A. A Meta-Analysis of 17 Randomized Trials of a PCI-Based Strategy in Patients With Stable Coronary Ar- tery Disease. J Am Coll Cardiol in press.
15. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. N Engl J Med 2007;356:1030-1039.
16. Lagerqvist B, James SK, Stenestrand U, et al. Long-Term Outcomes with Drug- Eluting Stents versus Bare-Metal Stents in Sweden. N Engl J Med 2007;356:1009- 1019.
17. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation. JAMA 2007;297:159-168.
18. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement: Results From the PREMIER Registry. Circulation 2006;113:2803-2809.
19. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. The Lancet 2007;370:937- 948.
20. Silber S, Borggrefe M, Böhm M, et al. Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamente freisetzenden Koronarstents (DES). Der Kardiologe 2007;1:84-111.
21. Nakagawa H, Jackman WM. Catheter Ablation of Paroxysmal Supraventricular Tachycardia. Circulation 2007;116:2465-2478.
22. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Man- agement of Patients With Atrial Fibrillation: A Report of the American College of Car- diology/American Heart Association Task Force on Practice Guidelines and the Euro- pean Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation):
Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-354.
23. Stevenson WG, Soejima K. Catheter Ablation for Ventricular Tachycardia. Circulation 2007;115:2750-2760.
24. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angio- tensin-converting-enzyme inhibitors: the CHARM-Alternative trial. The Lancet 2003;362:772-776.
25. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. The Lancet 2000;355:1582-1587.
26. The OI. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med 2008;358:1547-1559.
27. Cleland JGF, Daubert J-C, Erdmann E, et al. The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. N Engl J Med 2005;352:1539-1549.
28. Bax JJ, Abraham T, Barold SS, et al. Cardiac Resynchronization Therapy: Part 1-- Issues Before Device Implantation. Journal of the American College of Cardiology 2005;46:2153-2167.
29. Grube E, Schuler G, Buellesfeld L, et al. Percutaneous Aortic Valve Replacement for Severe Aortic Stenosis in High-Risk Patients Using the Second- and Current Third- Generation Self-Expanding CoreValve Prosthesis: Device Success and 30-Day Clini- cal Outcome. Journal of the American College of Cardiology 2007;50:69-76.
30. Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis: Guide- lines From the American Heart Association: A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiol- ogy, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007;116:1736- 1754.
